These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138 [TBL] [Abstract][Full Text] [Related]
7. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052 [TBL] [Abstract][Full Text] [Related]
8. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057 [TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226 [TBL] [Abstract][Full Text] [Related]
10. SHP-1 is a target of regorafenib in colorectal cancer. Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018 [TBL] [Abstract][Full Text] [Related]
11. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479 [TBL] [Abstract][Full Text] [Related]
12. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051 [TBL] [Abstract][Full Text] [Related]
13. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871 [TBL] [Abstract][Full Text] [Related]
14. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Huang CY; Tai WT; Wu SY; Shih CT; Chen MH; Tsai MH; Kuo CW; Shiau CW; Hung MH; Chen KF Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):761-71. PubMed ID: 26960749 [TBL] [Abstract][Full Text] [Related]
15. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173 [TBL] [Abstract][Full Text] [Related]
16. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Kuang S; Zhang J; Huang N; Zhang J; Chen B; Wang L; Liu M Mol Carcinog; 2024 Sep; 63(9):1738-1749. PubMed ID: 38837427 [TBL] [Abstract][Full Text] [Related]
17. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Huang CY; Lin CS; Tai WT; Hsieh CY; Shiau CW; Cheng AL; Chen KF Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):456-62. PubMed ID: 23474115 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624 [TBL] [Abstract][Full Text] [Related]
20. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]